Mechanism of gamma-secretase modulators
γ-分泌酶调节剂的机制
基本信息
- 批准号:10292930
- 负责人:
- 金额:$ 4.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-15 至 2022-07-14
- 项目状态:已结题
- 来源:
- 关键词:Abeta synthesisAcidsAcquired Immunodeficiency SyndromeActive SitesAffectAllosteric SiteAlzheimer&aposs DiseaseAmericanAmino AcidsAmyloidAmyloid beta-42Amyloid beta-ProteinAmyloid beta-Protein PrecursorAnimalsAspartic EndopeptidasesBindingBinding SitesBiologyBrainCatalytic DomainCategoriesCell LineCell SurvivalCellsChemicalsChemistryCleaved cellClinical TrialsCognitionCognitive deficitsComplexDevelopmentDiseaseDisease ProgressionDrug CombinationsDrug DesignDrug TargetingEvaluationEventExhibitsFDA approvedFailureGenerationsGoalsImidazoleIn VitroLabelLaboratoriesLengthLinkMalignant NeoplasmsMass Spectrum AnalysisMeasuresMemory LossMolecularMolecular ConformationMutationNatural ProductsNerve DegenerationNeurodegenerative DisordersNeuronsNon-Steroidal Anti-Inflammatory AgentsParentsPathogenesisPathogenicityPathologicPeptide HydrolasesPeptide MappingPeptidesPharmaceutical PreparationsProductionProteolysisResearchRoleSenile PlaquesSeriesSignal TransductionSiteSite-Directed MutagenesisStructural ModelsTestingToxic effectWorkabeta accumulationamyloid precursor protein processingbasecognitive performancecostdesigndrug developmentfamilial Alzheimer diseasegamma secretaseimprovedin vivoinhibitor/antagonistinsightmouse modelnotch proteinnovel therapeuticspreclinical studypresenilinpresenilin-1simulationstable cell linesynergism
项目摘要
Abstract
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder which currently affects 5.8
million Americans. However, there are currently no FDA-approved treatments capable of delaying or stopping
disease progression. Amyloid-beta (Aβ) plaques are believed to be integral to AD pathogenesis through their
role in the “amyloid cascade hypothesis,” in which the accumulation of Aβ peptides initiates a chain of
pathological events leading to neurodegeneration and ultimately AD. γ-secretase is an aspartyl protease
responsible for processing a wide range of substrates. It is considered an attractive drug target because it
cleaves amyloid precursor protein (APP) in the final step of proteolysis to generate Aβ peptides of varying
lengths; moreover, mutations in APP and presenilin, the catalytic subunit of γ-secretase, have been linked to
familial AD and shown to alter Aβ production. Unfortunately, all clinical trials of γ-secretase inhibitors proved
unsuccessful due to off target effects on other γ-secretase substrates, such as Notch. The failures of γ-
secretase inhibitors spurred the discovery and development of a new series of compounds known as γ-
secretase modulators (GSMs). A subset of NSAIDs were initially discovered to selectively reduce levels of the
pathogenic Aβ42 in favor of the less pathogenic Aβ38 without inhibition of Notch. Improvements on these
compounds led to second generation GSMs. This project will focus on two classes of second generation
GSMs: acid GSMs derived from NSAIDs and imidazole GSMs. Acid and imidazole GSMs have been
characterized by multiple groups and showed promise in decreasing pathogenic Aβ species while increasing
the less pathogenic species. However, they still demonstrated limitations in clinical trials regarding Aβ
selectivity, potency, and toxicity. Our objective is to define the molecular mechanism of GSMs in order to
improve them for AD drug development. Using GSM-based photoprobes to label γ-secretase, our laboratory
has found that acid and imidazole GSMs bind to distinct sites on the presenilin subunit of γ-secretase. Based
on this information, we hypothesize that acid and imidazole GSMs bind to distinct, allosteric sites of γ-
secretase and work in synergy to effectively modulate Aβ production. Using approaches at the interface of
biology and chemistry, this project aims to: 1) Determine the mechanism of binding of GSMs on γ-secretase
and 2) Determine the effects of GSM combination on Aβ production, toxicity, and cognition. To investigate the
molecular mechanisms of GSMs, we will use chemical probes combined with mass spectrometry and structural
modeling to identify the precise binding sites. We will also evaluate pairs of acid and imidazole GSMs in Aβ-
secreting cell lines and use the most effective concentrations to analyze toxicity and cognitive performance in
an AD mouse model. Overall, the proposed studies will enable us to decode the mechanism of GSMs and,
ultimately, develop GSMs with the highest selectivity and potency. Findings from this proposal will unlock new
possibilities for modulation of γ-secretase to more effectively treat AD.
摘要
阿尔茨海默病(AD)是一种破坏性的神经退行性疾病,目前影响5.8
百万美国人。然而,目前没有FDA批准的治疗方法能够延迟或停止
疾病进展。β淀粉样蛋白(A β)斑块被认为是AD发病机制的组成部分,通过其自身的免疫反应。
在"淀粉样蛋白级联假说"中的作用,其中A β肽的积累启动了一条链,
导致神经变性和最终AD的病理事件。γ-分泌酶是一种酰基蛋白酶
负责处理各种基板。它被认为是一个有吸引力的药物靶点,因为它
在蛋白水解的最后一步中切割淀粉样前体蛋白(APP),产生不同
此外,APP和早老素(γ-分泌酶的催化亚基)的突变与
家族性AD并显示改变A β产生。不幸的是,所有γ-分泌酶抑制剂的临床试验都证明,
由于对其他γ-分泌酶底物(如Notch)的脱靶效应而不成功。γ-
分泌酶抑制剂刺激了一系列新化合物的发现和开发,称为γ-
分泌酶调节剂(GSM)。最初发现NSAID的一个子集可以选择性地降低
致病性A β 42有利于致病性较低的A β 38,而不抑制Notch。这些方面的改进
第二代GSM的诞生。该项目将重点关注两类第二代
GSMs:源自NSAID和咪唑GSMs的酸性GSMs。酸和咪唑GSM已经被
以多组为特征,并显示出减少致病性A β种类,同时增加
致病性较低的物种。然而,他们在关于A β的临床试验中仍然表现出局限性,
选择性、效力和毒性。我们的目标是确定GSM的分子机制,
改进它们用于AD药物开发。利用基于GSM的光探针标记γ-分泌酶,
发现酸性和咪唑类GSMs与γ-分泌酶早老素亚基上的不同位点结合。基于
基于这一信息,我们假设酸和咪唑GSMs与γ-
分泌酶和协同作用,有效地调节A β的产生。使用接口的方法,
本项目的主要目的是:1)确定GSMs与γ-分泌酶结合的机制
和2)确定GSM组合对A β产生、毒性和认知的影响。探讨
GSMs的分子机制,我们将使用化学探针结合质谱和结构
建模以识别精确的结合位点。我们还将评估A β-
分泌细胞系,并使用最有效的浓度来分析毒性和认知性能,
AD小鼠模型。总的来说,拟议的研究将使我们能够解码GSM的机制,
最终,开发出具有最高选择性和效力的GSM。这项提案的结果将开启新的
调节γ-分泌酶以更有效地治疗AD的可能性。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Turning the tide on Alzheimer's disease: modulation of γ-secretase.
- DOI:10.1186/s13578-021-00738-7
- 发表时间:2022-01-04
- 期刊:
- 影响因子:7.5
- 作者:Luo JE;Li YM
- 通讯作者:Li YM
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joanna Luo其他文献
Joanna Luo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joanna Luo', 18)}}的其他基金
相似国自然基金
具有抗癌活性的天然产物金霉酸(Aureolic acids)全合成与选择性构建2-脱氧糖苷键
- 批准号:22007039
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
海洋放线菌来源聚酮类化合物Pteridic acids生物合成机制研究
- 批准号:
- 批准年份:2019
- 资助金额:10.0 万元
- 项目类别:省市级项目
手性Lewis Acids催化的分子内串联1,5-氢迁移/环合反应及其在构建结构多样性手性含氮杂环化合物中的应用
- 批准号:21372217
- 批准年份:2013
- 资助金额:80.0 万元
- 项目类别:面上项目
对空气稳定的新型的有机金属Lewis Acids催化剂制备、表征与应用研究
- 批准号:21172061
- 批准年份:2011
- 资助金额:30.0 万元
- 项目类别:面上项目
钛及含钛Lewis acids促臭氧/过氧化氢体系氧化性能的广普性、高效性及其机制
- 批准号:21176225
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
基于Zip Nucleic Acids引物对高度降解和低拷贝DNA检材的STR分型研究
- 批准号:81072511
- 批准年份:2010
- 资助金额:31.0 万元
- 项目类别:面上项目
海洋天然产物Makaluvic acids 的全合成及其对南海鱼虱存活的影响
- 批准号:30660215
- 批准年份:2006
- 资助金额:21.0 万元
- 项目类别:地区科学基金项目
相似海外基金
CAREER: Highly Rapid and Sensitive Nanomechanoelectrical Detection of Nucleic Acids
职业:高度快速、灵敏的核酸纳米机电检测
- 批准号:
2338857 - 财政年份:2024
- 资助金额:
$ 4.6万 - 项目类别:
Continuing Grant
Lipid nanoparticle-mediated Inhalation delivery of anti-viral nucleic acids
脂质纳米颗粒介导的抗病毒核酸的吸入递送
- 批准号:
502577 - 财政年份:2024
- 资助金额:
$ 4.6万 - 项目类别:
Double Incorporation of Non-Canonical Amino Acids in an Animal and its Application for Precise and Independent Optical Control of Two Target Genes
动物体内非规范氨基酸的双重掺入及其在两个靶基因精确独立光学控制中的应用
- 批准号:
BB/Y006380/1 - 财政年份:2024
- 资助金额:
$ 4.6万 - 项目类别:
Research Grant
Quantifying L-amino acids in Ryugu to constrain the source of L-amino acids in life on Earth
量化 Ryugu 中的 L-氨基酸以限制地球生命中 L-氨基酸的来源
- 批准号:
24K17112 - 财政年份:2024
- 资助金额:
$ 4.6万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Collaborative Research: RUI: Elucidating Design Rules for non-NRPS Incorporation of Amino Acids on Polyketide Scaffolds
合作研究:RUI:阐明聚酮化合物支架上非 NRPS 氨基酸掺入的设计规则
- 批准号:
2300890 - 财政年份:2023
- 资助金额:
$ 4.6万 - 项目类别:
Continuing Grant
Integrated understanding and manipulation of hypoxic cellular functions by artificial nucleic acids with hypoxia-accumulating properties
具有缺氧累积特性的人工核酸对缺氧细胞功能的综合理解和操纵
- 批准号:
23H02086 - 财政年份:2023
- 资助金额:
$ 4.6万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Basic research toward therapeutic strategies for stress-induced chronic pain with non-natural amino acids
非天然氨基酸治疗应激性慢性疼痛策略的基础研究
- 批准号:
23K06918 - 财政年份:2023
- 资助金额:
$ 4.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms how arrestins that modulate localization of glucose transporters are phosphorylated in response to amino acids
调节葡萄糖转运蛋白定位的抑制蛋白如何响应氨基酸而被磷酸化的分子机制
- 批准号:
23K05758 - 财政年份:2023
- 资助金额:
$ 4.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular recognition and enantioselective reaction of amino acids
氨基酸的分子识别和对映选择性反应
- 批准号:
23K04668 - 财政年份:2023
- 资助金额:
$ 4.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Synthetic analogues based on metabolites of omega-3 fatty acids protect mitochondria in aging hearts
基于 omega-3 脂肪酸代谢物的合成类似物可保护衰老心脏中的线粒体
- 批准号:
477891 - 财政年份:2023
- 资助金额:
$ 4.6万 - 项目类别:
Operating Grants














{{item.name}}会员




